Full Press Release Details
("Midatech", "Company"
Result of General Meeting
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that
the resolution concerning shareholder approval of the sale of Midatech Pharma US Inc. ("MTP US") was duly passed at
the General Meeting held earlier today, with 99.7% of votes received in favour of the resolution.
A further announcement will be made upon
completion of the sale, which is expected on or before 31 October 2018.
For more information, please contact:
Panmure Gordon (UK) Limited (Nominated Adviser and
Corporate finance: Freddy Crossley / Emma Earl
Corporate broking: James Stearns
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Nicholas
Westwicke Partners (US Investor Relations)
Midatech Pharma (LSE AIM: MTPH; NASDAQ:
MTP) is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing
a range of improved chemotherapeutics or new immunotherapeutics, using its three proprietary platform drug delivery technologies,
all of which are in the clinic, specifically:
Each of our three technologies are thus
focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can
exert their actions in an effective, safe and precise manner.
Midatech employs c. 70 staff and is headquartered in Oxfordshire, with an R&D facility in Cardiff
and a manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com.